Viral replication of SARS-CoV-2 could be self-limitative – The role of the renin-angiotensin system on COVID-19 pathophysiology

Rocha, Vinícius Novaes

doi:10.1016/j.mehy.2020.110330

Cited by 8 publications

(5 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Original article [17] Coronavirus disease 2019 (COVID-19): multisystem review of pathophysiology Review article [18] COVID-19: current understanding of its pathophysiology, clinical presentation and treatment Review article [19] Viral replication of SARS-CoV-2 could be self-limitative -the role of the renin-angiotensin system on COVID-19 pathophysiology…”

Section: Authorsmentioning

confidence: 99%

See 1 more Smart Citation

Building a Simple COVID-19 Knowledge Graph in Bahasa Indonesia: A Preliminary Study

Muharram,

Taufikulhakim,

Purwarianti

2024

Preprint

View full text Add to dashboard Cite

COVID-19 is an acute respiratory disease that has become a pandemic worldwide. Many studies have been conducted to enhance our understanding of COVID-19. However, the abundance of information obtained from these studies has resulted in information overload. In this study, we purposed a simple COVID-19 Knowledge Graph in Bahasa Indonesia as a way to reconstruct knowledge to combat this information overload. We used Bahasa Indonesia in our study to explore its potential for constructing a Knowledge Graph (KG). The construction of our KG involved manual curation of medical literatures and annotation of entities and relationships by the domain experts. The KG was implemented using Neo4J version 5. We successfully demonstrated our COVID-19 KG, which consists of 240 nodes and 276 relationships with 15 and 14 node and relationship labels respectively. Accessing the information within the KG is made effortless through the use of Cypher queries in Neo4J. Further research is still needed to develop the KG into a larger and better one. However, our COVID-19 KG can serve as a basis for further development.

show abstract

Section: Authorsmentioning

confidence: 99%

“…Coronavirus disease 2019 (also known as COVID- 19) is an acute respiratory infectious disease caused by the SARS-CoV-2 virus [1], [2]. COVID-19 was first identified as an outbreak in the city of Wuhan, Hubei province, China and has since become a pandemic worldwide.…”

Section: Introductionmentioning

confidence: 99%

Building a Simple COVID-19 Knowledge Graph in Bahasa Indonesia: A Preliminary Study

Muharram,

Taufikulhakim,

Purwarianti

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…[18][19][20] Once SARS-CoV-2 overwhelms the ACE2 receptors, functional inhibition of the alternative renin-angiotensin system (RAS) pathway occurs, leading to reduced expression of angiotensin (Ang) 1-7, which increases proinflammatory cytokines, resulting in systemic inflammation through the angiotensin 1 receptors. 28 This causes a concomitant increase in inflammatory cytokine levels, promoting pulmonary damage and ARDS. Furthermore, T cell depletion and exhaustion results in lymphopenia and the generation of dysfunctional lymphocytes, which is further worsened by direct damage to the lymphatic organs by the virus.…”

Section: Covid-19mentioning

confidence: 99%

“…Furthermore, T cell depletion and exhaustion results in lymphopenia and the generation of dysfunctional lymphocytes, which is further worsened by direct damage to the lymphatic organs by the virus. 28 , 29 Hyperactivation of the nuclear factor-kappa B (NF-кB) pathway is involved in local and systemic inflammation. A major pathway for NF-кB activation following coronavirus infection is the MyD88 pathway through PRRs, leading to the induction of proinflammatory cytokines.…”

Section: Immune Signatures and Pathogenesismentioning

confidence: 99%

Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients

Philips¹,

Rela²,

Soin³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

The novel coronavirus disease 2019 (COVID-19) pandemic has impacted health care worldwide, with specific patient populations, such as those with diabetes, cardiovascular disease, and chronic lung disease, at higher risk of infection and others at higher risk of disease progression. Patients with decompensated cirrhosis fall into the latter category and are a unique group that require specific treatment and management decisions because they can develop acute-on-chronic liver failure. In liver transplant recipients, the atypical immunity profile due to immunosuppression protects against downstream inflammatory responses triggered by COVID-19. This exhaustive review discusses the outcomes associated with COVID-19 in patients with advanced cirrhosis and in liver transplant recipients. We focus on the immunopathogenesis of COVID-19, its correlation with the pathogenesis of advanced liver disease, and the effect of immunosuppression in liver transplant recipients to provide insight into the outcomes of this unique patient population.

show abstract

“… 27 , 28 However, in stable cirrhosis, in the presence of highly up-regulated ACE2 receptors and higher expression of Ang 1-7, SARS-CoV-2 infection may not be uncontrollably detrimental and could be associated with better outcomes. 29 In decompensated cirrhosis, chronic activation of RAS and sympathetic nervous system activation and secretion of antidiuretic hormones occur in the presence of persistent arterial hypotension.…”

Section: Covid-19 and Chronic Liver Disease (Cld)mentioning

confidence: 99%

Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care

Philips¹,

Kakkar²,

Joseph³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

This eleventh review of global reporting of ADRs for drugs used to treat COVID-19 is as before mainly descriptive in nature. It includes reviews for the drugs that were initially included in WHO Solidarity trial to find an effective COVID-19 treatment and other drugs used for a COVID-19 indication where the number of reports in VigiBase exceeds 100. Regarding remdesivir, a major increase in reports was seen in this review. Notable numbers of reports for several non-labelled ADR terms have been shared within the system, described in the remdesivir section of the document. Concerning the other drugs reviewed, ADR-patterns are consistent with those described in earlier reports and mostly within the labelling for the respective drugs. Reports have been shared from all WHO regions, with the largest number now originating in the WHO region of the Americas with 45% of the shared reports (Table 2). WHO has announced the discontinuation of the hydroxychloroquine (HCQ) and lopinavir;ritonavir arms of the Solidarity trial as per the recommendation from the international steering committee 1 . The decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir;ritonavir in nonhospitalized patients or as pre-or post-exposure prophylaxis for COVID-19.

show abstract

Viral replication of SARS-CoV-2 could be self-limitative – The role of the renin-angiotensin system on COVID-19 pathophysiology

Cited by 8 publications

References 70 publications

Building a Simple COVID-19 Knowledge Graph in Bahasa Indonesia: A Preliminary Study

Building a Simple COVID-19 Knowledge Graph in Bahasa Indonesia: A Preliminary Study

Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients

Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care

Contact Info

Product

Resources

About